Gregory H. Gorman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gregory H. Gorman has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Alicia M. Neu
Johns Hopkins University School of Medicine, Baltimore, Maryland
2 shared publications Barbara Fivush
Departments of Pediatrics and Epidemiology
2 shared publicationsDiane Frankenfield
Departments of Pediatrics and Epidemiology
2 shared publications- Elizabeth Hisle-Gorman
Department of Pediatrics, Uniformed Services University of the Health Sciences , Bethesda, MD 20814
2 shared publications Matilda Eide
Department of Pediatrics, Walter Reed National Military Medical Center, 4954 North Palmer Rd., Bethesda, MD 20889
2 shared publications- Paul Schaettle
Knowesis, Inc. , Fairfax, VA 22031, USA
2 shared publications
Latest Publications
- Open Access
- 2 July 2022
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 187 (11-12) , 308-310
From the Defense Health Board: Military Accessions and the Continuum of Mental Health Research
The Defense Health Board conducted a year-long examination of mental health accession screening and related issues. In its August 2020 report, Examination of Mental Health Accession Screening: Predictive Value of Current Measures and Processes, the Board recommends a paradigm shift in how mental health impacts on readiness are understood and addressed. This shift can only occur with the development and implementation of a research plan that follows cohorts of military personnel from recruitment through their military career. The following article describes this research plan as an excerpt of the larger report.
- 2 July 2022
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 187 (11-12) , 308-310
Open AccessFrom the Defense Health Board: Military Accessions and the Continuum of Mental Health Research
The Defense Health Board conducted a year-long examination of mental health accession screening and related issues. In its August 2020 report, Examination of Mental Health Accession Screening: Predictive Value of Current Measures and Processes, the Board recommends a paradigm shift in how mental health impacts on readiness are understood and addressed. This shift can only occur with the development and implementation of a research plan that follows cohorts of military personnel from recruitment through their military career. The following article describes this research plan as an excerpt of the larger report.
- Open Access
- 9 July 2021
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 187 (1-2) , 12-16
Mobilizing the U.S. Military’s TRICARE Program for Value-Based Care: A Report From the Defense Health Board
The U.S. Military Health System spends about $50 billion annually to provide care to 9.6 million active duty service members, retirees, and their families through its TRICARE health plans. TRICARE follows the predominant payment model in the USA—fee-for-service—although the Department of Defense (DoD) and Congress encourage and mandate a move toward alternative payment models—mainly, fee-for-value. For the next TRICARE contracts which will begin in 2023, the DoD asked its health-focused federal advisory committee, the Defense Health Board (DHB), to recommend how best to assess and prioritize leading value-based healthcare initiatives identified from private, public, and employer-based health plans. The November 2020 report, ‘Modernization of the TRICARE Benefit’, specifies a rubric to evaluate these value-based care initiatives not only in traditional measures of effectiveness but also in terms of the Defense Health Agency’s Quadruple Aim with its focus on readiness. The goal of TRICARE’s move toward value-based care is to leverage its size and focus on prevention of disease and injury to maintain the readiness of the U.S. Armed Forces in addition to delivering great outcomes and value to the DoD’s nearly 10 million beneficiaries. The DHB emphasizes that TRICARE’s size and focus on providing quality care at lower cost will incentivize providers to participate in the shift toward value-based care despite the potential challenges in transitioning to this system. This shift also aims to motivate other large government and private payors to accelerate the adoption of value-based care through TRICARE’s example.
- 9 July 2021
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 187 (1-2) , 12-16
Open AccessMobilizing the U.S. Military’s TRICARE Program for Value-Based Care: A Report From the Defense Health Board
The U.S. Military Health System spends about $50 billion annually to provide care to 9.6 million active duty service members, retirees, and their families through its TRICARE health plans. TRICARE follows the predominant payment model in the USA—fee-for-service—although the Department of Defense (DoD) and Congress encourage and mandate a move toward alternative payment models—mainly, fee-for-value. For the next TRICARE contracts which will begin in 2023, the DoD asked its health-focused federal advisory committee, the Defense Health Board (DHB), to recommend how best to assess and prioritize leading value-based healthcare initiatives identified from private, public, and employer-based health plans. The November 2020 report, ‘Modernization of the TRICARE Benefit’, specifies a rubric to evaluate these value-based care initiatives not only in traditional measures of effectiveness but also in terms of the Defense Health Agency’s Quadruple Aim with its focus on readiness. The goal of TRICARE’s move toward value-based care is to leverage its size and focus on prevention of disease and injury to maintain the readiness of the U.S. Armed Forces in addition to delivering great outcomes and value to the DoD’s nearly 10 million beneficiaries. The DHB emphasizes that TRICARE’s size and focus on providing quality care at lower cost will incentivize providers to participate in the shift toward value-based care despite the potential challenges in transitioning to this system. This shift also aims to motivate other large government and private payors to accelerate the adoption of value-based care through TRICARE’s example.
- 10 September 2018
- Published by Springer Nature in Journal of Perinatology
- Vol. 38 (11) , 1573-1580
Suspected or known neonatal sepsis and neurodevelopmental delay by 5 years
Evaluate impact of known and suspected neonatal sepsis in the term and preterm infant on neurodevelopmental delay by 5 years. Included infants were born in 2009–2010 and followed for 5 years. Diagnostic codes and at least 5 days of antibiotic use identified suspected sepsis. Laboratory results confirmed known sepsis. Diagnostic codes stratified developmental delay by sub-type. Logistic regression analysis determined odds of developmental delay for sepsis and suspected sepsis. Of 65,938 included infants, 190 had sepsis and 3449 had suspected sepsis. After adjustment for known developmental risk factors, sepsis and suspected sepsis were associated with increased risk for any developmental delay, (1.48 (1.05–2.09) and 1.09 (1.01–1.18)), respectively, and multiple developmental delay sub-types. Neonatal sepsis and suspected sepsis are associated with neurodevelopmental delay by 5 years of age.
- 10 September 2018
- Published by Springer Nature in Journal of Perinatology
- Vol. 38 (11) , 1573-1580
Suspected or known neonatal sepsis and neurodevelopmental delay by 5 years
Evaluate impact of known and suspected neonatal sepsis in the term and preterm infant on neurodevelopmental delay by 5 years. Included infants were born in 2009–2010 and followed for 5 years. Diagnostic codes and at least 5 days of antibiotic use identified suspected sepsis. Laboratory results confirmed known sepsis. Diagnostic codes stratified developmental delay by sub-type. Logistic regression analysis determined odds of developmental delay for sepsis and suspected sepsis. Of 65,938 included infants, 190 had sepsis and 3449 had suspected sepsis. After adjustment for known developmental risk factors, sepsis and suspected sepsis were associated with increased risk for any developmental delay, (1.48 (1.05–2.09) and 1.09 (1.01–1.18)), respectively, and multiple developmental delay sub-types. Neonatal sepsis and suspected sepsis are associated with neurodevelopmental delay by 5 years of age.
- Open Access
- 1 October 2014
- Published by Defense Technical Information Center (DTIC)
Risk Factors, Comorbid Conditions, and Epidemiology of Autism in Children
Children with autism spectrum disorders (ASD) experience increased co-morbidities that affect their overall health and quality of life. Using a case:control cohort of children diagnosed with ASD in the Military Health System, the risk of having or developing specific conditions common to children or common to children with ASD was determined. Nutritional and gastrointestinal conditions were common. There was an increased risk of developing obesity and the components of metabolic syndrome (hypertension, hyperlipidemia, non-alcoholic steatoheapatitis). Despite that risk, children with ASD also were at risk of developing macronutrient and micronutrient deficiencies. There was no increased risk of eosinophilic esophagitis (EoE) in children with ASD, and the increased prevalence of EoE is mediated by the presence of a feeding disorder. In addition, children with ASD have an increased risk of developing complications from otitis media and appendicitis. This may be mediated by difficulties of inexperienced providers in examining children with ASD. Theses analyses have clarified the relative risk of co-morbidities that may be inherent to the behavioral issues of children with ASD.
- 1 October 2014
- Published by Defense Technical Information Center (DTIC)
Open AccessRisk Factors, Comorbid Conditions, and Epidemiology of Autism in Children
Children with autism spectrum disorders (ASD) experience increased co-morbidities that affect their overall health and quality of life. Using a case:control cohort of children diagnosed with ASD in the Military Health System, the risk of having or developing specific conditions common to children or common to children with ASD was determined. Nutritional and gastrointestinal conditions were common. There was an increased risk of developing obesity and the components of metabolic syndrome (hypertension, hyperlipidemia, non-alcoholic steatoheapatitis). Despite that risk, children with ASD also were at risk of developing macronutrient and micronutrient deficiencies. There was no increased risk of eosinophilic esophagitis (EoE) in children with ASD, and the increased prevalence of EoE is mediated by the presence of a feeding disorder. In addition, children with ASD have an increased risk of developing complications from otitis media and appendicitis. This may be mediated by difficulties of inexperienced providers in examining children with ASD. Theses analyses have clarified the relative risk of co-morbidities that may be inherent to the behavioral issues of children with ASD.
- Open Access
- 1 May 2014
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 179 (5) , 573-578
Attention Deficit Hyperactivity Disorder and Medication Use by Children During Parental Military Deployments
Parental deployment is associated with children's increased mental health needs. Attention Deficit Hyperactivity Disorder (ADHD) is the most common pediatric mental health diagnosis. We hypothesize children with ADHD will have increased mental health and medication needs during parental deployment. Retrospective cohort study of children with ADHD aged 4-8 years in the Military Health System. Of 413,665 children aged 4-8 years, 34,205 (8.3%) had ADHD and 19,123 (55.9%) of these were prescribed ADHD medications. During parental deployments, children with ADHD had a 13% increased rate of mental and behavioral health care visits (IRR 1.13 [95% CI 1.12-1.14; p < 0.00001]) and a decreased rate of medication changes (IRR 0.94 [95% CI 0.91-0.96; p < 0.00001]) compared to when parents were at home. Medication changes related to deployment varied by age; school-aged children had decreased medication events (IRR 0.88 [95% CI 0.86-0.91; p < 0.00001]) and preschool-aged children had increased medication events (IRR 1.05 [95% CI 1.02-1.10; p = .006]) during parental deployment. During parental deployment, children with ADHD aged 4-8 years have increased mental health visits and decreased ADHD medication changes. Younger children have increased medication changes, whereas older children have decreased changes during a parent's deployment.
- 1 May 2014
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 179 (5) , 573-578
Open AccessAttention Deficit Hyperactivity Disorder and Medication Use by Children During Parental Military Deployments
Parental deployment is associated with children's increased mental health needs. Attention Deficit Hyperactivity Disorder (ADHD) is the most common pediatric mental health diagnosis. We hypothesize children with ADHD will have increased mental health and medication needs during parental deployment. Retrospective cohort study of children with ADHD aged 4-8 years in the Military Health System. Of 413,665 children aged 4-8 years, 34,205 (8.3%) had ADHD and 19,123 (55.9%) of these were prescribed ADHD medications. During parental deployments, children with ADHD had a 13% increased rate of mental and behavioral health care visits (IRR 1.13 [95% CI 1.12-1.14; p < 0.00001]) and a decreased rate of medication changes (IRR 0.94 [95% CI 0.91-0.96; p < 0.00001]) compared to when parents were at home. Medication changes related to deployment varied by age; school-aged children had decreased medication events (IRR 0.88 [95% CI 0.86-0.91; p < 0.00001]) and preschool-aged children had increased medication events (IRR 1.05 [95% CI 1.02-1.10; p = .006]) during parental deployment. During parental deployment, children with ADHD aged 4-8 years have increased mental health visits and decreased ADHD medication changes. Younger children have increased medication changes, whereas older children have decreased changes during a parent's deployment.
- 1 February 2006
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 47 (2) , 285-293
Clinical Outcomes and Dialysis Adequacy in Adolescent Hemodialysis Patients
- 1 February 2006
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 47 (2) , 285-293
Clinical Outcomes and Dialysis Adequacy in Adolescent Hemodialysis Patients
- 18 August 2005
- Published by Springer Nature in Pediatric Nephrology
- Vol. 20 (12) , 1794-1800
Short stature and growth hormone use in pediatric hemodialysis patients
End-stage renal disease (ESRD) causes growth retardation in children, and poor growth has been linked to worse outcomes. Recombinant human growth hormone (rhGH) can increase growth velocity and final adult height in pediatric ESRD patients. We aimed to identify clinical predictors of short stature (height standard deviation score (Ht SDS) <−1.88) and rhGH use in short stature pediatric hemodialysis patients. In 2002, the Centers for Medicare & Medicaid Services (CMS) Clinical Performances Measures (CPM) ESRD Project collected demographic, clinical and laboratory data as well as rhGH use on all in-center hemodialysis patients in the US aged p p p p p p 2 (OR 3.1; 95% CI, 1.2–8.4; p <0.05). Increasing age and level of intact parathyroid hormone were not associated with rhGH use among short stature patients. A significant proportion of pediatric hemodialysis patients have short stature. The majority of short-stature patients are not receiving rhGH. Patients with short stature who are white, have longer durations on dialysis and have lower BMI are more likely to receive rhGH.
- 18 August 2005
- Published by Springer Nature in Pediatric Nephrology
- Vol. 20 (12) , 1794-1800
Short stature and growth hormone use in pediatric hemodialysis patients
End-stage renal disease (ESRD) causes growth retardation in children, and poor growth has been linked to worse outcomes. Recombinant human growth hormone (rhGH) can increase growth velocity and final adult height in pediatric ESRD patients. We aimed to identify clinical predictors of short stature (height standard deviation score (Ht SDS) <−1.88) and rhGH use in short stature pediatric hemodialysis patients. In 2002, the Centers for Medicare & Medicaid Services (CMS) Clinical Performances Measures (CPM) ESRD Project collected demographic, clinical and laboratory data as well as rhGH use on all in-center hemodialysis patients in the US aged p p p p p p 2 (OR 3.1; 95% CI, 1.2–8.4; p <0.05). Increasing age and level of intact parathyroid hormone were not associated with rhGH use among short stature patients. A significant proportion of pediatric hemodialysis patients have short stature. The majority of short-stature patients are not receiving rhGH. Patients with short stature who are white, have longer durations on dialysis and have lower BMI are more likely to receive rhGH.